Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib window of opportunity study in resectable ALK+ NSCLC
NCT05361564Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoint: Molecular candidates identified by analyzing scRNA-seq at 10 weeks. Status: unknown.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05361564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361564.